174 related articles for article (PubMed ID: 29227198)
21. The status of platinum anticancer drugs in the clinic and in clinical trials.
Wheate NJ; Walker S; Craig GE; Oun R
Dalton Trans; 2010 Sep; 39(35):8113-27. PubMed ID: 20593091
[TBL] [Abstract][Full Text] [Related]
22. Polymeric biomaterials for the delivery of platinum-based anticancer drugs.
Kim J; Pramanick S; Lee D; Park H; Kim WJ
Biomater Sci; 2015 Jul; 3(7):1002-17. PubMed ID: 26221935
[TBL] [Abstract][Full Text] [Related]
23. The drug targeting and delivery approach applied to pt-antitumour complexes. A coordination point of view.
Gabano E; Ravera M; Osella D
Curr Med Chem; 2009; 16(34):4544-80. PubMed ID: 19903151
[TBL] [Abstract][Full Text] [Related]
24. Recent Approaches to Platinum(IV) Prodrugs: A Variety of Strategies for Enhanced Delivery and Efficacy.
Najjar A; Rajabi N; Karaman R
Curr Pharm Des; 2017; 23(16):2366-2376. PubMed ID: 28155621
[TBL] [Abstract][Full Text] [Related]
25. New-generation platinum agents for solid tumors.
Shah N; Dizon DS
Future Oncol; 2009 Feb; 5(1):33-42. PubMed ID: 19243296
[TBL] [Abstract][Full Text] [Related]
26. Platinum formulations as anticancer drugs clinical and pre-clinical studies.
P Farrell N
Curr Top Med Chem; 2011; 11(21):2623-31. PubMed ID: 22039867
[TBL] [Abstract][Full Text] [Related]
27. Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches.
Galanski MS; Jakupec MA; Keppler BK
Curr Med Chem; 2005; 12(18):2075-94. PubMed ID: 16101495
[TBL] [Abstract][Full Text] [Related]
28. Recent Progresses in Conjugation with Bioactive Ligands to Improve the Anticancer Activity of Platinum Compounds.
Zuccolo M; Arrighetti N; Perego P; Colombo D
Curr Med Chem; 2022; 29(15):2566-2601. PubMed ID: 34365939
[TBL] [Abstract][Full Text] [Related]
29. Benefits of enhancing the platinum-free interval in the treatment of relapsed ovarian cancer: more than just a hypothesis?
Ledermann JA
Int J Gynecol Cancer; 2011 May; 21 Suppl 1():S9-11. PubMed ID: 21540669
[TBL] [Abstract][Full Text] [Related]
30. DNA damage induced by novel demethylcantharidin-integrated platinum anticancer complexes.
Pang SK; Yu CW; Au-Yeung SC; Ho YP
Biochem Biophys Res Commun; 2007 Nov; 363(1):235-40. PubMed ID: 17868646
[TBL] [Abstract][Full Text] [Related]
31. Beyond platinums: gold complexes as anticancer agents.
Nardon C; Boscutti G; Fregona D
Anticancer Res; 2014 Jan; 34(1):487-92. PubMed ID: 24403506
[TBL] [Abstract][Full Text] [Related]
32. Recent Advances in Platinum (IV) Complex-Based Delivery Systems to Improve Platinum (II) Anticancer Therapy.
Han X; Sun J; Wang Y; He Z
Med Res Rev; 2015 Nov; 35(6):1268-99. PubMed ID: 26280923
[TBL] [Abstract][Full Text] [Related]
33. Mechanistic and biological characteristics of different sugar conjugated 2-methyl malonatoplatinum(II) complexes as new tumor targeting agents.
Gao X; Liu S; Shi Y; Huang Z; Mi Y; Mi Q; Yang J; Gao Q
Eur J Med Chem; 2017 Jan; 125():372-384. PubMed ID: 27688191
[TBL] [Abstract][Full Text] [Related]
34. Research progress in modern structure of platinum complexes.
Bai L; Gao C; Liu Q; Yu C; Zhang Z; Cai L; Yang B; Qian Y; Yang J; Liao X
Eur J Med Chem; 2017 Nov; 140():349-382. PubMed ID: 28985575
[TBL] [Abstract][Full Text] [Related]
35. Novel platinum(IV) complexes conjugated with a wogonin derivative as multi-targeted anticancer agents.
Qin X; Xu G; Chen F; Fang L; Gou S
Bioorg Med Chem; 2017 Apr; 25(8):2507-2517. PubMed ID: 28314511
[TBL] [Abstract][Full Text] [Related]
36. EXAFS and IR structural study of platinum-based anticancer drugs' degradation by diethyl dithiocarbamate.
Bouvet D; Michalowicz A; Crauste-Manciet S; Brossard D; Provost K
Inorg Chem; 2006 Apr; 45(8):3393-8. PubMed ID: 16602799
[TBL] [Abstract][Full Text] [Related]
37. Platinum compounds in the treatment of advanced breast cancer.
MartÃn M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
38. Neuropilin-1-targeted gold nanoparticles enhance therapeutic efficacy of platinum(IV) drug for prostate cancer treatment.
Kumar A; Huo S; Zhang X; Liu J; Tan A; Li S; Jin S; Xue X; Zhao Y; Ji T; Han L; Liu H; Zhang X; Zhang J; Zou G; Wang T; Tang S; Liang XJ
ACS Nano; 2014 May; 8(5):4205-20. PubMed ID: 24730557
[TBL] [Abstract][Full Text] [Related]
39. Status of non-classical mononuclear platinum anticancer drug development.
Zhang J; Liu D; Li Y; Sun J; Wang L; Zang A
Mini Rev Med Chem; 2009 Oct; 9(11):1357-66. PubMed ID: 19929810
[TBL] [Abstract][Full Text] [Related]
40. The state-of-play and future of platinum drugs.
Apps MG; Choi EH; Wheate NJ
Endocr Relat Cancer; 2015 Aug; 22(4):R219-33. PubMed ID: 26113607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]